[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_2957",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_2957"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB00330"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "ethambutol hci is indicated for the treatment of pulmonary tuberculosis it should not be used as the sole antituberculous drug but should be used in conjunction with at least one other antituberculous drug selection of the companion drug should be based on clinical experience considerations of comparative safety and appropriate in vitro susceptibility studies in patients who have not received previous antituberculous therapy ie initial treatment the most frequently used regimens have been the following ethambutol hci plus isoniazid ethambutol hci plus isoniazid plus streptomycin in patients who have received previous antituberculous therapy mycobacterial resistance to other drugs used in initial therapy is frequent consequently in such retreatment patients ethambutol hci should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies antituberculous drugs used with ethambutol hci have included cycloserine ethionamide pyrazinamide viomycin and other drugs isoniazid aminosalicylic acid and streptomycin have also been used in multiple drug regimens alternating drug regimens have also been utilized"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/TreatmentIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB00330",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-06-29T08:05:23.509+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "ddIQY5D+AJSnoBJcYAqS7n1k2HYcvc1Ma5OStx4ElLzNJysqwWoGnuZIFUvxN0M+LeeL5E1AGNaRoSNymWNkeG1mrSmRFPeIy/kJ34qc78L3bk+DO0vtYxsFrVi2MnsJ5NIjjrfJRpQi1eAf/7Pw3DDWDhLWAf7cFsijMWbKWas="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY"
    } ]
  } ],
  "@id" : "http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#pubinfo"
} ]